



Plasma Extracellular Vesicle MicroRNA Profiles as Emerging Biomarkers of Frontotemporal Dementia

Kerina Elmer*

Department of Neurodegenerative Medicine, University of Sao Paulo, Sao Paulo, Brazil

DESCRIPTION

Frontotemporal Dementia (FTD) is a group of progressive neurodegenerative disorders characterized primarily by changes in behavior, personality, executive abilities, language and social functioning. Unlike some other forms of dementia, memory impairment may be less prominent during the early stages, making recognition and accurate classification difficult. The biological diversity of FTD further complicates diagnosis because several molecular pathways and pathological processes can produce overlapping clinical manifestations. Plasma-derived extracellular vesicles and their micro Ribonucleic Acid (RNA) cargo have emerged as promising sources of molecular information that may help characterize these processes through minimally invasive blood-based measurements. Extracellular vesicles are small membrane-enclosed particles released by many types of cells. They circulate through biological fluids and can transport proteins, lipids, messenger RNA, microRNA and other molecular components between cells. Their lipid membranes can protect enclosed molecules from degradation, allowing biological information to remain detectable in the circulation. Because extracellular vesicles may originate from neurons, glial cells, endothelial cells and peripheral tissues, their molecular contents can reflect changes occurring within different biological systems.

MicroRNAs are short, non-coding RNA molecules that regulate gene activity after transcription. A single microRNA can influence multiple messenger RNAs, while several microRNAs can collectively regulate a particular cellular pathway. Changes in microRNA abundance may therefore accompany alterations in inflammation, synaptic function, mitochondrial activity, protein processing, neuronal survival and cellular stress. In neurodegenerative conditions, these regulatory molecules may provide information about disease-associated biological changes that are not readily captured by conventional clinical assessments. The analysis of microRNAs contained within

plasma extracellular vesicles is particularly attractive because vesicle-associated molecules may be more stable than freely circulating RNA. Isolation of extracellular vesicles from plasma can be followed by extraction and molecular profiling of their RNA contents. Distinctive microRNA patterns could then be evaluated in relation to clinical characteristics and other biological indicators of FTD. Rather than relying on one molecule, a combination of several microRNAs may provide a more informative molecular signature because FTD involves multiple interconnected cellular pathways.

Potential FTD-associated microRNA signatures may reflect processes affecting neuronal communication and cellular maintenance. Altered regulation of synaptic genes could contribute to changes in neuronal connectivity, while microRNAs associated with inflammatory pathways might reflect activation of immune-related mechanisms within the nervous system. Other signatures may involve mitochondrial regulation, oxidative balance, apoptosis or protein homeostasis. The presence of such molecular patterns in circulating vesicles could provide an indirect window into biological processes occurring in the brain. Another important consideration is the clinical heterogeneity of FTD. The condition includes behavioral and language-predominant presentations and different individuals can have different underlying pathological characteristics. MicroRNA profiles might eventually help distinguish biological subtypes or identify molecular patterns associated with particular clinical manifestations. Such information could complement neurological examination, neuropsychological assessment, structural imaging and other molecular indicators rather than replacing established diagnostic approaches.

The usefulness of a circulating microRNA signature depends heavily on reproducible sample handling and analytical procedures. Plasma composition can vary considerably among individuals and factors such as age, medication use, systemic

Correspondence to: Kerina Elmer, Department of Neurodegenerative Medicine, University of Sao Paulo, Sao Paulo, Brazil, Email: kerina.elmer@neuromed.ufsp.br

Received: 30-Aug-2025, Manuscript No. JDMGP-25-32405; **Editor assigned:** 02-Sep-2025, PreQC No. JDMGP-25-32405; **Reviewed:** 16-Sep-2025, QC No. JDMGP-25-32405; **Revised:** 22-Sep-2025, Manuscript No. JCRB-26-32316; **Published:** 30-Sep-2025, DOI: 10.35248/2153-0602.25.16.393

Citation: Elmer K (2025). Plasma Extracellular Vesicle MicroRNA Profiles as Emerging Biomarkers of Frontotemporal Dementia. J Data Mining Genomics Proteomics. 16:393.

Copyright: © 2025 Elmer K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

inflammation, metabolic conditions and lifestyle may influence circulating extracellular vesicles. Differences in vesicle isolation methods, RNA extraction techniques, normalization procedures and detection platforms can also produce variation in reported microRNA levels. Consistent laboratory procedures are therefore essential for developing reliable molecular profiles. Bioinformatic analysis provides another important component of microRNA interpretation. Because microRNAs regulate numerous targets, identifying a biological pattern requires integration of expression measurements with predicted or experimentally supported gene targets and relevant cellular pathways. Computational approaches can help identify groups of microRNAs that collectively distinguish FTD-associated molecular states. Combining these signatures with clinical information and neuroimaging may ultimately improve the precision of patient classification.

The potential clinical value of plasma extracellular vesicle microRNAs extends beyond diagnosis. Molecular profiles could

eventually assist with identifying individuals at different stages of disease progression or estimating the likelihood of particular clinical trajectories. They may also provide indicators of biological responses to future therapeutic interventions. However, a molecular signature must demonstrate consistent performance across independent patient populations before it can be considered suitable for routine clinical use. The development of blood-based biomarkers for FTD is therefore closely connected to advances in extracellular vesicle biology, RNA technologies and computational analysis. MicroRNAs carried by plasma extracellular vesicles offer a combination of biological relevance, molecular stability and accessibility that makes them attractive candidates for further investigation. Their greatest potential may come from multi-marker signatures capable of capturing several aspects of neurodegenerative biology simultaneously.